<DOC>
	<DOCNO>NCT00710034</DOCNO>
	<brief_summary>For primary goal , hypothesize 1 ) oral tobacco product efficacious medicinal nicotine product substitute smoking cigarette ; 2 ) among non-abstainers , oral tobacco product lead great reduction cigarette smoke medicinal nicotine ; 3 ) high rate oral tobacco compare medicinal nicotine use observe beyond treatment period . For secondary goal , hypothesize 1 ) product equally reduce withdrawal symptom negative affect cigarette abstinence , smoker assign oral tobacco product likely report like effect assign product compare smoker assign medicinal nicotine ; 2 ) great physiological effect ( e.g. , vitals ) observe oral tobacco product compare medicinal nicotine ; 3 ) toxicant exposure toxicity reduce dramatically smoker switch cigarette product ; however , reduction great use medicinal nicotine ; 4 ) although abstinence rate higher oral tobacco product , initial product cost low , relative medicinal nicotine intervention , likelihood long duration oral tobacco use increase oral tobacco cost time user ; 5 ) switch low-nitrosamine oral tobacco reduce life-years lose compare continue smoke cost-effective ( term life-years save ) substitution strategy compare medicinal nicotine .</brief_summary>
	<brief_title>Efficacy Oral Tobacco Products Compared Medicinal Nicotine</brief_title>
	<detailed_description>This second study `` Oral Tobacco Harm Reduction Product '' grant clinical trial . Subjects randomize brand smokeless tobacco determine effective Study 1 nicotine gum 12 week compare complete substitution smoking . The secondary aim determine effect product biomarkers exposure toxicity . If sample size sufficient , comparison make across product measure control amount tobacco use . Other secondary aim include examine reliability biological measure control group continue smoke , extent constituent extraction oral pouch tobacco use , relationship extent constituent extraction biomarkers exposure , finally , withdrawal symptom oral tobacco product . Two site use study : University Minnesota Oregon Research Institute ( ORI ) .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>smoke least 10 cigarette daily past year , good physical health ( unstable medical condition ; contraindication medicinal nicotine , appropriate study , stable , good mental health ( e.g. , recent unstable untreated psychiatric diagnosis , include substance abuse , determine DSMIV criterion ) . Subjects must currently use tobacco nicotine product ; Female subject pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Oral Tobacco Products</keyword>
	<keyword>Snus</keyword>
	<keyword>Smoking Substitution</keyword>
	<keyword>Harm Reduction</keyword>
	<keyword>Biomarkers Tobacco Exposure</keyword>
</DOC>